The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients;Stȩżenie metaloproteinazy 9 i 2 w surowicy chorych na niedrobnokomórkowego raka płuca

Polski Merkuriusz Lekarski

Volumn 22, Issue 132, 2007, Pages 539-541

  Kopczyńska, Ewa ^a   Dancewicz, Maciej ^b,d   Kowalewski, Janusz ^b,d   Kardymowicz, Hanna ^c,e   Tyrakowski, Tomasz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Katedra i Klinika Chirurgii Klatki Piersiowej i Nowotworów   (Poland)

^c Regional Oncology Centre Bydgoszcz   (Poland)

^d Nicolaus Copernicus University ^*

^e Oncology Centre of Bydgoszcz   (Poland)

Author keywords

Metalloproteinase 9 and 2; Non small cell lung cancer

Indexed keywords

GELATINASE A; GELATINASE B; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 34547354194     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cairns R.A., Khokha R., Hill R.P.: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med., 2003, 3, 659-671.
2. Iizasa T., Fujisawa T., Suzuki M. i wsp.: Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin. Cancer Res. 1999, 5, 149-153.
3. Ishikawa S., Takenaka K., Yanagihara K. i wsp.: Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin. Cancer Res., 2004, 10, 6579-6585.
4. Jackson Ch.: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens., 2002, 11, 295-299.
5. Jumper C., Cobos E., Lox C.: Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir. Med., 2004, 98, 2, 173-177.
6. Khasigov P.Z., Podobed O.V., Gracheva T.S. i wsp.: Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry, 2003, 68, 7, 711-717.
7. Koc M., Ediger D., Budak F. i wsp.: Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial fluid in patients with lung cancer. Tumori, 2006, 92, 2, 149-154.
8. Laack E., Kohler A., Kugler C. i wsp.: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann. Oncol. 2002, 13, 1550-1557.
9. Leinonen T., Pirinen R., Bohm J. i wsp.: Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer, 2006, 51, 3, 313-321.
10. Ludwig T.: Local proteolytic activity in tumor cell invasion and metastasis. BioEssays, 2005, 27, 1181-1191.
11. Lynch C.C., Matrisian L.M.: Matrix metalloproteinases in tumor - host cell communication. Differentiation, 2002, 70, 561-573.
12. Ming S., Sun T., Xiao W. i wsp.: Matrix metalloproteinases-2, -9 and tissue inhibitor of metallo-proteinase-1 in lung cancer invasion and metastasis. CMJ, 2005, 118, 1, 69-72.
13. Moche M., Hui D.S., Huse K. i wsp.: Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion. Pneumologie, 2005, 59, 8, 523-528.
14. Nabeshima K., Inoue T., Shimao Y. i wsp.: Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol. Int., 2002, 52, 255-264.
15. Ohbayashi H.: Matrix metalloproteinases in lung diseases. Curr. Protein and Peptide Sci., 2002, 3, 409-421.
16. Ondo K., Sugio K., Yamazaki K. i wsp.: The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer. Cancer, 2004, 46, 2, 205-213.
17. Papliński Z., Jassem J.: Rak płuca. PZWL, Warszawa 1994.
18. Parks W.C., Shapiro S.D.: Matrix metalloproteinases in lung biology. Respir. Res., 2001, 2, 10-19.
19. Rundhaug J.E.: Matrix metalloproteinases, angiogenesis, and cancer. Clin. Cancer Res., 2003, 9, 551-554.
20. Sasaki H., Kiriyama M., Fukai I. i wsp.: Elevated serum pro-MMP2 levels in patients with advanced lung cancer are not suitable as a prognostic marker. Surg. Today, 2002, 32, 1, 93-95.
21. Shou Y., Hirano T., Gong Y. i wsp.: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br. J. Cancer, 2001, 85, 11, 1706-1712.
22. Tamura M., Oda M., Matsumoto I. i wsp.: The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann. Surg. Oncol., 2004, 11, 10, 928-933.
23. Zhao J., Liu X.Y., Zhang Q.Y. i wsp.: Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi, 2005, 27, 11, 676-679.
24. Yang S.F., Hsieh Y.S., Lin C.L. i wsp.: Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin. Chim. Acta, 2005, 354, 1-2, 91-99.